碳酸酶抑制剂和激活剂的多药理学
Alessandro Bonardi1, Claudiu T Supuran1
1Neurofarba Department, Section of Pharmaceutical Sciences, University of Florence, Sesto Fiorentino, Florence, Italy.
Expert opinion on pharmacotherapy
|February 28, 2025
概括
碳酸酶 (CA) 抑制剂用于青光眼,和癌症,通常会影响多个标. 了解这种多药理学有助于设计用于复杂疾病的新药.
科学领域:
- 酶学 是一种酶学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 碳酸 anhydrases (CA) 是生理和病理过程中的关键酶.
- 抗CA抑制剂在临床上用于治疗包括玻璃眼,,肥胖和癌症在内的疾病.
- 碳酸激酶激活剂 (CAAs) 尚未在临床使用中.
研究的目的:
- 审查碳酸酶抑制剂和激活剂的多药效应.
- 探索CA抑制在现有药物的治疗作用和副作用中的作用.
- 讨论设计新型药物的潜力,针对多因子疾病的碳酸无水酶.
主要方法:
- 在过去20年的PubMed和ScienceDirect数据库中进行文献搜索.
- 鉴定具有显著碳酸酶抑制作用的药物,包括抗药,抗精神病药,抗炎药和抗癌药.
- 来自各种氨基酸类的碳酸酶激活剂的综述.
主要成果:
- 许多药物,包括托皮拉,尼萨米德,切莱科西布和帕佐帕尼布,显著抑制人类CA异型,影响多个标.
- 这些药物的多药理学从化学,结构和药理学的角度来研究.
- 还讨论了作为CA激活剂的氨基化合物.
结论:
- CA调节器的多药理学为药物设计提供了机会.
- 了解与多个目标的相互作用可以为复杂的,多因素条件的新疗法的开发提供信息.
- 向碳酸无水酶为创新药物发现提供了一个有前途的途径.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
447
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
447
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
363
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
Bicarbonate-Carbonic Acid Buffer
580
The carbonic acid-bicarbonate buffer system is critical for maintaining the body's pH balance. It operates on the equilibrium:
580
Antihypertensive Drugs: Potassium-Sparing Diuretics
433
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
433
Antihypertensive Drugs: Direct Renin Inhibitors
468
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
468
Antihypertensive Drugs: Angiotensin II Receptor Blockers
568
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
568


